To co-develop and co-commercialize MK-6070, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager, worldwide except for Japan where Merck retains exclusive rights
Data showed that the primary endpoint of recurrence-free survival (RFS) met the pre-specified futility criteria
Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications
Sales reflect continued strong growth in oncology and vaccines
Acquisition broadens oncology pipeline with a portfolio of novel T-cell engagers including HPN328 (MK-6070), an investigational delta-like ligand 3 (DLL3) targeting T-cell engager
PharmaLogic will assist ARTBIO with radiochemistry and supply of the finished radiopharmaceutical product for future Phase I and II clinical trials of AB001 from their facility in New York
Acquisition includes HPN328, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager being evaluated in certain patients with small cell lung cancer and neuroendocrine tumors
This agreement includes upfront and milestone payments with a combined potential value of over $500m and sales royalties.
Innovent also obtains an exclusive option to license in the future development, manufacturing and commercialization rights of SGB-3908
Cullgen will have the option during the initial stages of clinical development to participate equally in the costs, profits and losses
Subscribe To Our Newsletter & Stay Updated
